
By Blake Brittain
Jan 6 (Reuters) - Bayer's Monsanto sued COVID-19 vaccine makers Pfizer, BioNTech and Moderna in Delaware federal court on Tuesday for allegedly misusing its messenger RNA technology in manufacturing their vaccines, a Bayer spokesperson confirmed.
The patent infringement lawsuits said the companies copied technology developed by Monsanto in the 1980s for strengthening mRNA in crops in order to stabilize the genetic material used in their vaccines.
Bayer separately filed a similar lawsuit against Johnson & Johnson in New Jersey federal court on Tuesday, arguing that a DNA-based process J&J used in manufacturing its shots infringed the patent.
Bayer's complaints add to a web of patent lawsuits over the blockbuster COVID shots, which include an ongoing lawsuit filed by Moderna against Pfizer in 2022.
Bayer was not involved in developing COVID vaccines and does not make or sell any version of them. It asked the courts for an unspecified amount of monetary damages and said it was not seeking to block the companies from manufacturing their vaccines.
Pfizer and BioNTech earned more than $3.3 billion in revenue from global sales of their vaccine Comirnaty in 2024, while Moderna earned $3.2 billion from its Spikevax, according to company reports, a fraction of their sales at the height of the pandemic.
Johnson & Johnson stopped selling its COVID vaccine in the United States in 2023.
Bayer's lawsuits said Monsanto scientists pioneered technology in the 1980s for reducing mRNA instability to make more pest-resistant crops. Bayer alleged that Pfizer and Moderna utilized technology for improving the stability of mRNA that infringes one of its patents.
(Reporting by Blake Brittain in WashingtonEditing by Bill Berkrot)
LATEST POSTS
- 1
Misremembering might actually be a sign your memory is working optimally - 2
French Senate debates social media ban for under-15s - 3
NATO needs Ukraine's 'adaptation DNA' and an 'HOV lane' for new war tech, top commander says - 4
Why the Houthis waited until now to strike - 5
Top German court to rule on claims by Wirecard shareholders
Amplifying Cash The executives: The Upsides and downsides of Various Ledgers
‘More should be done’: UN pushes Syrian regime on justice for Druze, Alawites and minority groups
7 Countries Where Newcomers Feel Most Welcome, and 3 Where They Often Don’t
Flu illness count nears 5 million, with New York City among the hardest hit
November Lease Deals for the 2025 Kia EV6 are Too Good to Pass Up
Monetary Strengthening: Assuming Command over Your Cash
Oldest sequenced RNA reveals details about a mammoth’s final moments 40,000 years
6 Useful Home Espresso Machines
Is an $85 apple pie worth it? Our Thanksgiving taste test says … maybe.













